Clinical Update on Hyperlipidemia Management: Advanced Risk Assessment, New Guidelines, and New Treatments to Improve CVD Outcomes

Thursday, June 1st | 7:15 - 9:00 pm ET

Early identification of risk for or development of atherosclerosis with monitoring and management of LDL-C and Lp(a) levels allows enhanced primary and secondary cardiovascular disease prevention. An increased focus on the reduction of atherosclerosis and the prevention of cardiovascular events can reduce the lifetime risk of CVD for the individual patient and also prolong length and quality of life on a population basis, given that cardiovascular disease remains the leading cause of death globally. To accomplish this goal, the healthcare community must keep pace with a growing body of research involving still-novel therapies, such as PCSK9 and siRNA, to lower LDL-C and control atherosclerosis progression. In this program our expert faculty will provide a practical analysis and discussion of recent clinical trial data for these and other newer therapeutics, highlighting management approaches that are currently available and emerging.

Hosted by The National Lipid Association. Dinner Provided by the NLA

Supported by an educational grant from Novartis.

Alan S. Brown, MD, MNLA (Course Chair)

Jessica M. Peña, MD, MPH, FNLA

Nataliya Pyslar, MD, FNLA

James A. Underberg, MD, MS, MNLA


Straight From the Experts: Clinical Conversations on Modernizing Hyperlipidemia Management With PCSK9-Targeting Agents

Friday, June 2 | 7:00 – 8:30am ET

Elevated low-density lipoprotein cholesterol (LDL-C) levels are associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD)—justifying the guidance from multiple professional societies that emphasize the importance of lowering LDL-C to reduce cardiovascular risk. Despite the availability of nearly ten different classes of medications indicated to lower cholesterol levels, dyslipidemia is not appropriately managed for many patients, resulting in target LDL-C goals not being achieved. How can clinicians best improve and individualize dyslipidemia care?

Hosted by The National Lipid Association. Breakfast Provided by the NLA


P. Barton Duell, MD, FNLA

Bruce A. Warden, PharmD, CLS, FNLA


The Evolving Narrative of HDL-C: Contemporary Insights on Quality vs. Quantity for Targeting Cardio Protection

Friday, June 2 | 6:15 – 8:00pm ET

The future of HDL as a biomarker for CVD is rapidly evolving, and new information regarding the structural and functional capacity of HDL is emerging. We invite you to attend this two-hour, CME-certified symposium that will feature three leading experts in the field of lipidology as they focus on addressing the HDL hypothesis, what we have learned from the past, and its potential for the future. Expert faculty will provide insights into clinical trials and what those clinical trials have taught us about HDL-C-elevating therapies as compared to trials focusing on HDL function for primary and secondary cardio prevention.

Hosted by The National Lipid Association. Dinner Provided by the NLA


Christie Ballantyne, MD, FNLA

Vera Bittner, MD, MSPH, MNLA

Robert S. Rosenson, MD, FNLA


Making a Differential Diagnosis

Saturday, June 3 | 6:45 – 8:45am ET

Rare diseases are complicated and often not enough is known about these disorders that can have devastating health outcomes, high morbidity, and can impair quality of life. Lack of understanding about the disorder often leads to lengthy setbacks in diagnosis and is often misdiagnosed which leads to poor health consequences for patients. During this symposium, expert faculty will provide practical information for making the diagnosis of a rare disease and will be joined by a live patient speaker to discuss their journey to obtaining a proper diagnosis.

Hosted by the National Lipid Association. Breakfast provided by the NLA.


Zahid Ahmad, MD, FNLA

Elif A. Oral, MD, MS

Daniel Soffer, MD, FNLA

Kathleen Wyne, MD, PhD, FNLA